The p14 ARF protein, the product of an alternate reading frame of the INK4A/ARF locus on human chromosome 9p21, disrupts the ability of MDM2 to target p53 for proteosomal degradation and causes an increase in steady-state p53 levels, leading to a G 1 and G 2 arrest of cells in the cell cycle. Although much is known about the function of p14 ARF in the p53 pathway, not as much is known about its function in human tumor growth and chemosensitivity independently of up-regulation of p53 protein levels. To learn more about its effect on cellular proliferation and chemoresistance independent of p53 up-regulation, human HT-1080 fibrosarcoma cells null for p14 ARF and harboring a defective p53 pathway were stably transfected with p14 ARF cDNA under the tight control of a doxycyclineinducible promoter. Induction of p14 ARF caused a decrease in cell proliferation rate and colony formation and a marked decrease in the level of dihydrofolate reductase (DHFR) protein. The effect of p14 ARF on DHFR protein levels was specific, because thymidylate kinase and thymidylate synthase protein levels were not decreased nor were p53 or p21WAF1 protein levels increased. The decrease in DHFR protein was abolished when the cells were treated with the proteasome inhibitor MG132, demonstrating that p14 ARF augments proteasomal degradation of the protein.
INTRODUCTION
The INK4A/ARF locus on human chromosome 9p21 codes for the p16INK4A and the p14 ARF protein. The p16INK4A protein is the product of alternatively spliced exons 1␣, 2, and 3 and functions as a cyclin-dependent kinase inhibitor, regulating the G 1 -phase exit by inhibiting the phosphorylation of the retinoblastoma protein (1) (2) (3) . The p14 ARF protein (p19 ARF in mouse) is transcribed from distinct exon 1␤ and shared exons 2, and 3 and has been shown to bind the MDM2 protein, alleviating MDM2-driven degradation of p53, which results in elevated p53 levels that lead to cell cycle arrest in the G 1 -S and G 2 -M boundaries of the cell cycle (4, 5) . Induction of ARF has been shown to occur in response to proliferative signals such as myc, E1A, Ras, and E2F-1 (6 -9) . Thus, induction of ARF provides a link between retinoblastoma protein and p53 tumor-suppressive pathways. However, p19
ARF also causes a G 1 -phase cell cycle arrest independent of p53 (10) . This finding is not surprising, because tumors exist in which p53 and p14 ARF are inactivated, indicating that p14 ARF may have other functions (10 -12) . It has been shown recently that p14 ARF and p19
ARF are able to bind to E2Fs and alter their transcriptional ability and stability, possibly explaining why ARF is able to inhibit cell cycle progression independent of p53 (13) (14) (15) .
Although much is known about the function of ARF in the p53 pathway, less is known about its functions in human tumor growth and chemosensitivity independently of its regulation of p53 via binding to MDM2. Mouse embryonic fibroblasts expressing E1A and exogenous ARF are more sensitive to killing by doxorubicin than their normal counterparts that only express E1A (7) . Alterations in the INK4A/ ARF locus reduce p53 induction and cytotoxicity of cyclophosphamide in mouse lymphomas (16) . Also, recombinant adenovirus-mediated p14
ARF overexpression sensitizes MCF-7 breast cancer cells to cisplatin (17) . Thus, expression of ARF appears to increase sensitivity to chemotherapeutic drugs. However, this increase in sensitivity has been associated with up-regulation of p53. The question of whether p14 ARF can also increase sensitivity to chemotherapeutics independently of p53 up-regulation has remained unanswered. To investigate the effect of p14 ARF on growth and sensitivity to chemotherapeutic agents independent of p53 up-regulation, we transfected the HT-1080 human fibrosarcoma cell line that lacks p14 ARF and harbors a nonfunctional p53 pathway (18 -20) with the pTET-ON, pTRE2 vector containing p14 ARF cDNA, in which expression is tightly regulated by doxycycline. Herein, we report that restoration of p14 ARF causes a marked decrease in dihydrofolate reductase (DHFR) protein levels by altering DHFR protein stability; decreases the proliferation rate of these cells by reducing colony formation; and selectively confers resistance to the antifolates methotrexate, trimetrexate, and raltitrexed by increasing the reliance of these cells on thymidine salvage.
Rad assay. Fifty g of protein were analyzed on SDS-PAGE (varying between 12% and 14% depending on protein analyzed). The proteins were electroblotted onto nitrocellulose membrane and probed with the appropriate primary and secondary antibodies. The protein bands were visualized on X-ray film using the enhanced chemiluminescence reagent from Amersham Biosciences (Arlington Heights, IL). The p21 (F-5) and p53 (Bp53-12) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The polyclonal thymidine kinase (TK) antibody was a gift from Dr. T. Kelly (Memorial Sloan Kettering Cancer Center, New York). The polyclonal thymidilate synthase (TS) antibody was a gift from Dr. F. Maley (Wadsworth Center, New York State Department of Health, Albany, NY).
The ␣-tubulin antibody (B-5-1-2) was purchased from Sigma (St. Louis, MO), and the p14 ARF antibody (NB 200-111) was purchased from Novus Biologicals (Littleton, CO).
mRNA Analysis. Cells were grown for various times in the presence or absence of 1 g/ml doxycycline, collected, and lysed; mRNA was isolated using the Invitrogen mRNA isolation kit, and reverse transcriptase reaction performed using the Invitrogen cDNA cycle kit. The relative message quantity was analyzed using probe and primers specific for DHFR cDNA as described previously (21) . In brief, PCR was performed by using a TaqMan 1,000 RXN Gold with buffer A kit and the ABIPrism 7700 thermocycler (Applied Biosystems). The temperature profile was 95°C, 10 min (1 cycle); and T1, 95°C, 15 s; T2, 60°C, 60 s (42 cycles). The primer and probe sequences are listed below. The first primer is the TaqMan probe, the second primer is the forward PCR primer, and the third primer is the reverse PCR primer. The DHFR primer and probe sequences are as follows: (a) TTGGTTCGCTAAACTG-CATCGTCGC; (b) GTCCTCCCGCTGCTGTCAT; and (c) ATGCCCATGT-TCTGGGACAC.
Growth Assays and Fluorescence-Activated Cell Sorter Analysis. The short-term growth assay was carried out by plating 50,000 cells in each well of a six-well plate in growth medium, with or without doxycycline. Every 24 h, starting on the day of plating, cells exposed or not exposed to 1 g/ml doxycycline cells were detached from the wells by treatment with 0.25% trypsin/0.25% EDTA, resuspended in 1 ml of growth medium, and counted using the Coulter Counter ZM from Coulter Electronics (Hialeah, FL). The percentage of viable cells was determined by trypan blue staining. The experiment was repeated three times. For the long-term survival assay, 1,000 cells were plated in each well of a six-well plate in growth medium with or without 1 g/ml doxycycline; and 14 days later, the medium was removed, and the cells were washed with PBS and then stained with 2% crystal violet solution. For thymidine deplete media studies, FBS was incubated with thymidine phosphorylase (TP) at 37°C for 1 h and then incubated at 65°C for 30 min to inactivate the enzyme, and the serum was finally added to RPMI 1640 at a concentration of 10%. For cell cycle analysis, asynchronous cells were grown for 48 h in the presence or absence of 1 g/ml doxycycline. Cells were collected and then fixed with ice-cold 70% methanol. DNA was stained with propidium iodide (Sigma) as described previously (22) . The stained cells were then analyzed on a Becton Dickinson fluorescence-activated cell sorter.
Cytotoxicity Assay. For cytotoxicity studies, 1,000 cells were plated in each well of 96-well microtiter plates (plating density approximately the same as the one used in short-term growth assay) in replicates of six, with or without 1 g/ml doxycycline in regular growth medium or in medium in which thymidine was depleted using TP. The following drugs were added at the indicated concentrations 24 h later and left in the medium for 96 h. Methotrexate, trimetrexate, raltitrexed, and cytarabine were added at concentrations ranging from 256 pM to 100 M. Doxorubicin was added at concentrations of 51 pM to 10 M, and hydroxyurea was added at concentrations of 26 nM to 2 mM. After 96 h, a solution containing 1 mg/ml 2,3-bis[2-methoxy-4nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide sodium salt (XTT) and 25 M phenazine methosulfate was added to achieve a final concentration of 0.2 mg/ml XTT and 5 M phenazine methosulfate and incubated for 2-4 h at 37°C, and absorbance was measured at 450 nm with a microplate reader, as described previously (23) . The above experiments were repeated at least three times.
TK Activity Assay. This is a modification to a previously shown method (24, 25) . In brief, cells treated or not treated with 1 g/ml doxycycline were incubated at 37°C for 72 h, then lysed in 50 mM Tris-HCl (pH 7.9), containing 1 mM ␤-mercaptoethanol, by three repeated freeze-thaw cycles, centrifuged, and the supernatant recovered. Four g of whole-cell protein lysate were added to a reaction mix consisting of 10 M thymidine, 50 mM Tris-HCl, 5 mM MgCl 2 , 5 mM ATP, 4 mM DTT, 10 mM NaF, and 1 Ci tritiated thymidine (25-l reaction). The mixture was incubated at 37°C for 20, 40, and 60 min. At each time point, 20 l were withdrawn and spotted on DE-81 filter paper. The filter paper was allowed to dry, washed three times in 5 mM ammonium formate, and placed in a scintillation vial containing 10 ml of Scintiverse BD scintillation fluid; and radioactivity was determined.
In Situ (Whole-Cell) Thymidylate Synthesis Activity Assay. This method has been described previously (26, 27) . In brief, p14JM cells were resuspended in growth medium at concentration of 2 ϫ 10 6 cells/ml and placed in 1.5-ml Eppendorf tubes. The cells were incubated for 3 h at 37°C. After the 3 h incubation, [5- 3 H]deoxyuridine solution was added in 40-l volume to cells to achieve a final concentration of 2 Ci/ml. At time points of 0, 15, 30, and 45 min, a 100-l cell suspension from the induced or uninduced cells was aliquoted to a separate tube containing 200 l of charcoal suspension and vortexed. The tubes were then centrifuged for 5 min at 15,000 rpm. The supernatant (100 l) was then added to 5 ml of scintillation mixture in 20-ml scintillation vials and counted in a scintillation counter. Samples were counted in the order of 0, 15, 30, and 45 min. A set of four samples plus the corresponding time points were used to calculate slope. Thymidylate synthesis activity is expressed as cpm/min/10 7 cells and calculated as follows: Activity (cpm/min/10 7 cells) ϭ [slope/cell number] ϫ 10 7 .
Analysis of Intracellular Tritium-Labeled Thymidine Metabolites.
Cells were plated in 100-mm plates. One batch of cells was treated with 1 g/ml doxycycline. After 72 h, the doxycycline-treated and untreated groups were incubated for an extra 4 h in the presence of 25 M thymidine containing 10 Ci [methyl-
3 H]thymidine. The cells were then trypsinized and collected by centrifugation. After washing with cold PBS, resuspended cells were transferred to a 1.5-ml tube and centrifuged for 15 s at 12,000 ϫ g at 4°C.
Pellets were immediately resuspended in 0.3 ml of 0.6 M trichloroacetic acid (4°C) and incubated at 4°C for 10 min followed by centrifugation. The acid supernatant was recovered and added to an equal volume of cold freon containing 0.5 M tri-n-octylamine. The mixture was vortexed for 15 s and centrifuged for 30 s at 12,000 ϫ g. The aqueous upper phase was recovered and analyzed by high performance liquid chromatography, as described previously (28) . Thymidine metabolite peaks from cell extracts were identified by comparison of retention times using thymidine mono-, di-, and triphosphates as standards.
Proteasome Inhibitor MG-132 Assay. Cells treated or not treated with 1 g/ml doxycycline for 48 h were treated or not treated with 100 nM MG-132 (Calbiochem, La Jolla, CA) or 0.1% DMSO for 12 h. Cells were lysed, and proteins analyzed by Western blotting.
Protein Synthesis Inhibition Assay. Cells treated or not treated with 1 g/ml doxycycline for 24 h were treated for various times with 10 g/ml cycloheximide. Cells were then harvested, whole-cell lysate was recovered, and proteins were analyzed by Western blotting. The approximate half-life of DHFR was determined by averaging band intensity of at least three separate experiments for the various time points by use of Image-Pro Plus software.
RESULTS

Selection of a p14
ARF -pTRE2-Inducible Clone. After screening several clones, one clone designated p14JM was isolated that expressed p14
ARF in the presence of 1 g/ml doxycycline. Expression of p14 ARF was detected by the appearance of a band that comigrated with another band detected in BT-549 cells that are known to express p14 ARF (Fig. 1A) . Induction of p14 ARF could be detected 8 h after exposure to 1 g/ml doxycycline, with maximal expression occurring at 24 h (data not shown). Induction of p14 ARF was detected with concentrations as low as 100 ng/ml doxycycline, with maximal induction occurring at 1 g/ml doxycycline (Fig. 1B) .
Induction of p14 ARF in HT-1080 Cells Inhibits Cellular Proliferation and Colony Formation. ARF has been shown to induce cell cycle arrest in a p53-dependent and -independent manner (4, 5, 10) . To examine whether p14 ARF restoration had any effect on growth rate in the HT-1080 cells, the effect of expressing p14 ARF on p14JM cell survival was examined using a clonogenic assay. ARF was reduced by more than 50% compared with cells that were not induced ( Fig. 2A) . This was not due to a doxycycline-induced increase in p53 or p21 levels (Fig. 2B) . The effect of p14 ARF on the short term growth of p14JM cells was also examined by seeding cells with or without doxycycline (1 g/ml) for 5 days. The doxycycline-treated cells expressing p14 ARF had a slower growth rate than that of the untreated cells not expressing p14 ARF (Fig. 2C) . One reason for the reduced colony formation and growth rate of the p14 ARF -expressing cells might be the ability of p14 ARF to arrest cells in G 1 (4, 6) . When cells were stained with propidium iodide and analyzed by fluorescence-activated cell sorting, there was a modest increase in the amount of cells in G 1 versus S phase in the induced cells (Fig. 2D) , with no change in the amount of cells in sub-G 1 (data not shown). Therefore, the increase in the amount of cells in G 1 observed indicated that p14 ARF is affecting the progression of cells from G 1 to S, rather than due to an increase in cell death. In addition, no difference was observed in the percentage of viable cells between the induced and uninduced cells, as measured by trypan blue staining after 72 h of doxycycline induction. p14 ARF Expression Decreases DHFR Stability in a ProteosomeDependent Manner. DHFR is a key enzyme in the de novo pathway for thymidylate synthesis, allowing for the recycling of dihydrofolate, the product of this reaction, to tetrahydrofolate. One of the expected consequences of inhibiting this enzyme would be the decreased production of thymidylate and therefore a reduction in DNA replication, leading to a decrease in growth rate. Induced expression of p14 ARF resulted in a greater than 9-fold decrease in DHFR protein levels beginning at 48 h, with no significant effect on the levels of TK or TS (Fig. 3A, 1 and 3) . There was no significant decrease of DHFR protein levels seen in the first 24 h of p14 ARF induction (data not shown). Addition of the same concentration of doxycycline for 72 h did not affect DHFR levels in HT-1080 parental cells (Fig. 3A, 2 ). There was a small difference in DHFR mRNA levels between the induced and uninduced cells, as shown by quantitative PCR (Fig. 3B) , indicating that this decrease was primarily posttranscriptional. This decrease, which may be related to the known effect of p14 ARF on E2F1 transcription, would not explain the large difference in DHFR protein levels. Addition of cycloheximide to inhibit protein translation revealed a decreased stability of DHFR in the presence of p14 ARF expression; the t 1/2 of DHFR changed from over 20 to 8 h (Fig. 3C) . When p14JM cells were exposed to 100 nM proteasome inhibitor MG-132, upon induction with p14 ARF , there was complete restoration of DHFR protein levels (Fig. 3D) . These results indicate that p14 ARF affects DHFR protein stability via increased proteasomal degradation. The decreased stability of DHFR upon p14 ARF induction appears to be indirect, because efforts to detect p14 ARF -DHFR binding were unsuccessful (data not shown). ARF conferred resistance to all three drugs (Fig. 4A) . In particular, compared with uninduced cells, the expression of p14 ARF was associated with marked resistance to methotrexate and raltitrexed, even at very high concentrations of these drugs. In contrast, when cytotoxicity experiments were carried out using hydroxyurea, doxorubicin, or cytarabine, also S-phase inhibitors with different mechanisms of action, there were no differences in cytotoxicity observed in the absence or presence of p14 ARF expression (Fig. 4B) . Therefore, p14
ARF expression selectively altered resistance to the antifolates methotrexate, trimetrexate, and raltitrexed. Because FBS contains high levels of thymidine (29 -31) , the possibility that increased thymidine salvage explained the resistance to the antifolates was examined. Cytotoxicity studies were conducted in the presence of 10% FBS depleted of thymidine, by pretreating serum with TP (32). In the presence of thymidine-depleted FBS, the resistance conferred by p14 ARF expression to methotrexate, trimetrexate, and raltitrexed was completely abolished (Fig. 4C) . Although depletion of thymidine did not affect the sensitivity profile of doxorubicin or cytarabine (data not shown), to rule out an effect of doxycycline on antifolate sensitivity, parental HT-1080 cells were separately treated with methotrexate, in the presence or absence of 1 g/ml doxycycline; no difference in cytotoxicity was observed (data not shown). Because human serum contains less thymidine than FBS or mouse serum (29 -31), we repeated the methotrexate cytotoxicity experiment in p14JM cells uninduced and induced to express p14 ARF in 10% FBS thymidinedepleted medium, in which physiological levels for humans (10
ARF inhibition of DHFR protein by proteosomal degradation. A, 1, Western blot with each respective antibody of p14JM lysates of cells that were allowed to reach confluency, detached, replated, and incubated with (ϩDOX) or without (ϪDOX) 1 g/ml doxycycline (DOX) for various amounts of time. 2, as a control, HT-1080 parental cells treated (ϩDOX) or not treated (ϪDOX) with 1 g/ml doxycycline for 72 h were also subjected to Western analysis using DHFR and tubulin antibodies as described above. 3, the p14JM whole-cell lysates from cells incubated with (ϩDOX) or without (ϪDOX) 1 g/ml doxycycline for 72 h for the TS and TK Western blots were electrophoresed on a separate polyacrylamide gel and blotted simultaneously with the TK and TS primary antibody. B, relative DHFR mRNA levels using TaqMan quantitative reverse transcription-PCR analysis (probe and primers specific for DHFR cDNA and normalized by actin message levels) of p14JM cells that were allowed to reach confluency, replated, incubated in the presence (ϩDOX) or in the absence (ϪDOX) of 1 g/ml doxycycline, and allowed to grow for various amount of time. Average values for three experiments of DHFR/ACTIN ratios are shown with their respective SD. C, p14JM cells incubated with (ϩDOX) or without (ϪDOX) 1 g/ml doxycycline for 24 h were treated with 10 g/ml cycloheximide. Right panel, at the indicated times, cells were lysed and Western blot was performed using DHFR and ␣-tubulin antibodies. Intensity of protein bands at different time points after cycloheximide addition relative to band intensity at the 0-h time point was plotted. Left panel, graph represents average and SDs of at least three separate experiments. D, cells were incubated with (ϩ) or without (Ϫ) 1 g/ml doxycycline for 48 h, and 100 nM MG-132 or 0.1% DMSO was added for 12 h. The cells were then lysed, and Western blots were performed using the antibodies as described above. were restored, and a difference in sensitivity to methotrexate was still observed (Fig. 4D) . p14 ARF Confers Resistance to Antifolates by Altering the Balance of Thymidine Supply. The fact that resistance to antifolates was abolished upon depleting the serum of thymidine indicated that expression of p14 ARF may increase thymidine salvage by either increasing thymidine uptake and/or increasing TK activity. Cells were collected 72 h post induction with 1 g/ml doxycycline and lysed, and TK activity was measured. There was no difference in TK activity between the cells uninduced and induced to express p14 ARF (Fig. 5A) . In another experiment, radiolabeled thymidine-treated cells were also collected at 72 h and analyzed for thymidine mono-, di-, and triphosphates by high performance liquid chromatography. There were no differences found in the thymidine metabolite peak profiles between doxycycline-treated and untreated cells (Fig. 5B) . Thus neither TK activity nor thymidine uptake or anabolism explained the thymidine reversal of antifolate resistance. Other mechanisms of known antifolate resistance include decreased influx of drug, decreased polyglutamate formation, and increased DHFR expression (33) . The fact that resistance is seen also with trimetrexate, which does not use the same active transport mechanism as methotrexate, renders impaired uptake an unlikely mechanism of resistance. Confirming this observation, uptake of tritiated methotrexate was similar in the p14 ARF -expressing and non-p14 ARF -expressing cells (data not shown). Decreased polyglutamylation and retention as a mechanism of resistance was ruled out by the fact that these cells were incubated continuously in the presence of drugs and therefore polyglutamylation would not affect cytotoxicity, due to the continuous availability of the extracellular level of the drug (34) and by the fact that trimetrexate does not undergo polyglutamylation. Paradoxically, resistance of p14JM cells to antifolates occurred in a situation in which DHFR protein levels were not increased but rather were drastically decreased. An explanation for this finding lies in the understanding of the balance between de novo thymidylate synthesis and the salvage pathway for thymidylate. DHFR is an important enzyme in the de novo pathway in that it provides the necessary reduced folate cofactor, 5,10 methylene tetrahydrofolate, for the conversion of dUMP to dTMP via reduction of dihydrofolate to tetrahydrofolate and subsequent conversion to 5,10-methylene tetrahydrofolate via serine hydroxy methyl transferase. However, dTMP can also be generated via thymidine in the medium. As a consequence of the marked decrease in DHFR activity, p14JM cells that are induced to express p14 ARF would be depleted of 5,10-methylene tetrahydrofolate. This in turn would cause a decrease in TS activity and therefore a reduction in the amount of de novo dTMP being produced. Fig. 5C shows that indeed, whole-cell thymidylate synthesis activity is decreased. Because the supply of thymidine is not reduced, as seen by the unaltered TK activity and thymidine pools (Fig. 5, A and B) in the p14 ARF -express- ARF -expressing cells shifts to thymidine salvage. These cells will therefore be more reliant on extracellular thymidine for growth, as seen by their greater decrease in colony formation when grown long-term in thymidine deplete medium, compared with p14JM cells that are not expressing p14 ARF (7-fold decrease versus 2-fold decrease for cells not expressing p14 ARF ; Fig. 5D ) and therefore are less sensitive to drugs that inhibit the de novo pathway of dTMP synthesis.
DISCUSSION
The p53-dependent effects of ARF have been widely studied (35, 36) . However, p53-independent effects of ARF have just recently been described (10, (13) (14) (15) . An important question left unanswered has been the effect of p14 ARF on chemosensitivity. Although a few studies have attempted to answer this question (7, 16, 17, 37) , in most cases, tumors with an intact p53 response pathway have been used as the model. In this study, we used a human HT-1080 fibrosarcoma cell line, which is null for p14 ARF and harbors a nonfunctional p53 pathway (18 -20) . Although p53 is expressed in this cell line, it is nonfunctional, as demonstrated by the lack of a G 1 -S block after treatment with ␥ radiation or N-(phosphonacetyl)-L-aspartic acid (18) . The reasons for its lack of function are unclear. MDM2 is also expressed in HT-1080 cells, and the expression of relatively high levels of p53 levels suggests that perhaps MDM2 in this cell line is mutated or nonfunctional. p14 ARF protein expression was induced using a doxycycline-inducible system, thus eliminating clonal variation. Upon induction of p14 ARF , we observed a decreased growth rate, decreased colony formation, selective resistance to antifolates, and increased dependence of the p14JM p14 ARF -induced cells on thymidine salvage, in the face of a marked decrease in DHFR protein levels.
The decrease in growth rate observed upon induction of p14 ARF demonstrates that p14 ARF is able to inhibit growth, independent of its ability to increase p53 protein levels. The decrease in cell growth may be explained by a delay in S-phase entry. It has been shown that p19 ARF , the mouse homologue of p14 ARF , can arrest cells at G 1 independently of p53, but the arrest occurs in the absence of MDM2 (10) . Because HT-1080 cells express high levels of MDM2 (20) , this may explain the lack of a more pronounced G 1 -S cell cycle arrest after p14 ARF induction. However, the decrease in cellular proliferation rate was delayed until 48 h after induction of p14 ARF , at which time a decrease in DHFR protein levels and an increase in the amount of cells in G 1 were seen, all consistent with a more delayed p53-independent response to ARF expression (10) . TK and TS levels were not altered after p14 ARF expression. Therefore, the decrease in cell growth after restoration of p14 ARF expression is not due to a general decrease in expression of cell cycle genes but rather to a more targeted event. Induction of p14 ARF is associated with a decrease in DHFR protein levels in p14JM cells, and therefore a slowdown in proliferation may be due in part to the lack of generation of reduced folate pools, i.e., 5,10-methylene tetrahydrofolate, needed in for conversion of dUMP to dTMP by TS. A decrease in whole-cell TS activity was observed correlating with decreased DHFR activity. p14 ARF and p19 ARF are able to bind to E2F-1 and alter its transcriptional activity and stability (13) (14) (15) . Although neither a decrease in E2F-1 protein levels, nor a significant change in DHFR mRNA levels was found after p14 ARF induction in p14JM cells, inhibition of E2F-1 transcription for other E2F-1 targets cannot be ruled out. We also cannot rule out the involvement of other downstream targets of p14 ARF that have not yet been discovered. An explanation for the decrease in DHFR levels after p14 ARF Fig. 5 . p14 ARF alters the balance of thymidine supply. A, p14JM cells were incubated with (ϩDOX) or without (ϪDOX) 1 g/ml doxycycline (DOX) for 72 h, lysed, and protein extracted for TK activity assay (see "Materials and Methods"). TK activity, as measured by radioactivity per 4 g of whole-cell extract every 20 min for 1 h, was plotted against time. The results are the average of three experiments, and the error bars represent the respective SD. B, p14JM cells were plated in the presence (ϩDOX) or absence (ϪDOX) of 1 g/ml doxycycline. After 72 h, cells were collected, and extracts were analyzed by high performance liquid chromatography, as described in "Materials and Methods." The collected samples were then counted for radioactivity and converted to cpm/ 3.0 ϫ 10 6 cells. restoration is a decrease in DHFR stability, reversed in the presence of the proteasome inhibitor MG-132. Therefore, p14 ARF expression may augment proteasomal degradation of DHFR. Although Martelli et al. (14) has found that p19 ARF is capable of targeting E2Fs for proteasomal degradation through direct binding of ARF to E2Fs, we were not able to show p14 ARF binding to DHFR. Although there are studies that have provided information on DHFR stability in other cell lines (38) , there is no information dealing specifically with the mechanisms of endogenous DHFR degradation. One possible mechanism of action is one in which p14
ARF interferes with the basal DHFR degradation machinery in increasing the activity of proteins that normally augment its degradation, decreasing the activity of proteins that stabilize it, or through a combination of both, possibly involving ubiquitination.
Another important finding in our study is the observation that expression of p14 ARF renders p14JM cells resistant to antifolates. This finding may seem counterintuitive due to the fact that a known cause of methotrexate or trimetrexate antifolate resistance is increased levels of DHFR. An explanation for this result is that thymidine is known to rescue cells from methotrexate inhibition, and antifolate sensitivity depends on the balance between de novo dTMP synthesis and thymidine salvage (39) . In the de novo pathway, dTMP is synthesized by TS from dUMP, using the reduced folate 5,10-methylene tetrahydrofolate as a cofactor. In thymidine salvage, thymidine is taken up by the cell and converted to dTMP via TK. In p14JM cells, induction of p14 ARF causes a marked decrease in DHFR protein levels, which in turn causes an inhibition of de novo dTMP synthesis. However, because there is no decrease in TK activity or in thymidine levels, p14 ARF expression creates a situation in which the salvage to de novo dTMP synthesis balance is shifted to salvage. Although growth is suboptimal, addition of drugs that inhibit the de novo pathway such as trimetrexate, methotrexate, or raltitrexed in a p14 ARF -expressing cell will be less cytotoxic in the presence of thymidine in the medium, due to the fact that these cells are more reliant on extracellular thymidine for growth; in the absence of thymidine, cell growth is markedly slowed. Hence, depletion of thymidine via TP treatment of FBS from the medium in p14 ARF -expressing cells restores the sensitivity of these cells to methotrexate, trimetrexate, and raltitrexed. Because incubation of p14 ARF -expressing p14JM cells with 1 ϫ 10 Ϫ7 M concentration of thymidine, levels that are physiological in humans, also resulted in these cells being resistant to the antifolates, these results are not an artifact of the very high thymidine levels found in FBS (29 -31) . p14 ARF expression in p14JM cells, through mechanisms still to be determined, increases DHFR proteasomal degradation and in so doing provides an explanation for the decrease in cell growth in the absence of an active p53 pathway. This decrease in cell growth is accentuated in the absence of thymidine in the medium. Although earlier studies have demonstrated that ARF expression contributes to drug sensitivity, we show that in a situation in which the p53 pathway is not active, p14
ARF causes resistance to antifolates. Antifolates are used for the treatment of leukemias, lymphomas, breast cancer, and other tumors (33) . This study has relevance to human cancer in that many tumors harbor p53 mutations and also express p14 ARF (5) and would be expected to be less sensitive to antifolates.
